Cullinan Therapeutics CGEM

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing first- or best-in-class therapies for autoimmune diseases and cancer. The company leverages its expertise in T cell engagers, a class of biologics that redirect the immune system to target and eliminate diseased cells, to advance a pipeline of high-impact drug candidates. Operating at the intersection of immunology and oncology, Cullinan Therapeutics prioritizes scientifically rigorous innovation to address unmet medical needs in complex and debilitating conditions. Its mission centers on delivering transformative treatments that establish new standards of care for patients.

The company generates revenue primarily through collaboration agreements and milestone payments tied to the development and commercialization of its drug candidates. While Cullinan Therapeutics does not yet have approved products on the market, it stands to receive upfront fees, development cost-sharing, regulatory milestone payments, and royalties from partners such as Taiho Pharmaceutical. For example, the company is eligible for up to $130 million in regulatory milestone payments and 50% of pre-tax profits from U. S. sales of zipalertinib, an EGFR inhibitor developed in partnership with Taiho. Additional revenue streams may emerge from licensing agreements, such as the $20 million upfront payment to Genrix for rights to velinotamig, with potential future milestones totaling $692 million.

The company operates through the following segments:

• Immunology: This segment focuses on developing T cell engagers for autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. Lead candidates include CLN-978, a CD19xCD3 bispecific T cell engager, and velinotamig, a BCMAxCD3 bispecific T cell engager licensed from Genrix. CLN-978 is currently in Phase 1 clinical trials across multiple autoimmune indications, with initial data expected in 2026. Velinotamig is being evaluated in China by Genrix, with global development rights held by Cullinan Therapeutics for all fields outside Greater China.
• Oncology: This segment advances therapies for hematologic malignancies and solid tumors, with a focus on acute myeloid leukemia and non-small cell lung cancer. Key assets include CLN-049, a FLT3xCD3 bispecific T cell engager for relapsed or refractory AML, which has received Fast Track designation from the FDA. The company also collaborates with Taiho on zipalertinib, an oral EGFR inhibitor targeting exon 20 insertion mutations in NSCLC, which is nearing regulatory submission for accelerated approval in the U. S.

Cullinan Therapeutics occupies a competitive position in the biopharmaceutical industry, particularly in the development of T cell engagers for autoimmune diseases and oncology. Its pipeline targets high-value therapeutic areas with significant unmet needs, positioning the company alongside established players like Amgen, Roche, and AstraZeneca, as well as emerging biotech firms such as Xencor and Regeneron. Competitive advantages include the company’s focus on differentiated bispecific antibodies with potential for broader patient applicability, off-the-shelf administration, and deeper tissue penetration compared to monoclonal antibodies or CAR T therapies. In oncology, CLN-049’s ability to target both mutated and wild-type FLT3 distinguishes it from approved FLT3 inhibitors, which are limited to specific genetic subsets of AML. The collaboration with Taiho on zipalertinib further strengthens its market position by leveraging a partner with commercialization expertise in oncology.

The company’s customer base consists primarily of patients with autoimmune diseases and cancer, as well as healthcare providers and institutions that prescribe and administer its therapies. While no commercial products are currently available, Cullinan Therapeutics’ clinical trials enroll patients with conditions such as systemic lupus erythematosus, rheumatoid arthritis, acute myeloid leukemia, and non-small cell lung cancer. Its partners, including Taiho Pharmaceutical and Genrix, represent key stakeholders in the development and future commercialization of its drug candidates. The company’s focus on severe and treatment-resistant diseases positions it to serve specialized medical centers, academic hospitals, and oncology clinics globally.